Dr. Peter Joseph Sunenshine, MD

Dr. Sunenshine practices at Banner Alzheimer's Institute in Phoenix, Arizona.

Dr. Sunenshine's NPI, 1487610937, was assigned on April 25, 2006. Dr. Sunenshine graduated from Rutgers New Jersey Medical School in 1998. Dr. Sunenshine's Arizona license number on file is 35513.

Dr. Sunenshine's primary practice is Banner Alzheimer's Institute, at 901 E Willetta St Fl 3 Fl 3, Phoenix, AZ 85006-2528. The practice phone is (602) 839-6901.

Dr. Sunenshine's primary practice is Banner Alzheimer's Institute in Phoenix, Arizona. Dr. Sunenshine is also affiliated with Banner - University Medical Center Phoenix. The medical group on file is Banner Medical Group. Dmand AI also links Dr. Sunenshine to 4 more hospitals, 10 medical groups and 3 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sunenshine practices, 9 sites in all. Vendor and product names are available with a free account.

Neuroradiology is Dr. Sunenshine's primary specialty in the NPI Registry, under taxonomy code 2085N0700X. Dr. Sunenshine is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Sunenshine's licenses on file in 11 states: Arizona, Oregon, Colorado, California, Virginia, Florida, New Jersey, New York, Hawaii, Wisconsin and Ohio.

CMS data shows 812 Medicare services from Dr. Sunenshine across 25 procedure codes in 2024, for 541 Medicare patients. Medicare paid $104,124 for them.

CMS counts 541 Medicare patients who saw Dr. Sunenshine in 2024. The largest group is 65 to 74, with 234 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 30% are also on Medicaid. Their average risk score is 2.14, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sunenshine's median patient age at 59, with 50% women.

In 2024, Dr. Sunenshine wrote 56 Medicare Part D claims for 16 patients. 79% of them were for generic drugs. CMS names the drug for 27 of them, across 1 drug with 11 or more claims each, at $102 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Sunenshine for performance year 2024, reported through an alternative payment model (APM). Dr. Sunenshine accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 7 papers to Dr. Sunenshine, published from 2017 to 2024. 2023 was the busiest year, with 2. The most frequent topics are Bone Neoplasms, Pain and Palliative Care. Dr. Sunenshine has published most often in Front Neurol. Dr. Sunenshine's most frequent co-authors are Aamir Badruddin, MD, Sandeep Bagla, MD and Mark Douglas Bain, MD.

CMS Open Payments shows 435 general payments to Dr. Sunenshine from 35 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 80% of the total. Medtronic USA, Inc. paid the most, $197,733.

Dr. Sunenshine graduated from Rutgers New Jersey Medical School in 1998.

Dr. Sunenshine is in network with 19 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.